Skip to main content

O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Publication ,  Journal Article
Raj, N; Klimstra, DS; Horvat, N; Zhang, L; Chou, JF; Capanu, M; Basturk, O; Do, RKG; Allen, PJ; Reidy-Lagunes, D
Published in: Pancreas
July 2017

OBJECTIVES: Alkylating agents have activity in well-differentiated pancreatic neuroendocrine tumors (WD panNETs). In glioblastoma multiforme, decreased activity of O-methylguanine DNA methyltransferase (MGMT) predicts response; in panNETs, MGMT relevance is unknown. METHODS: We identified patients with WD panNETs treated with alkylating agents, determined best overall response by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, and performed MGMT activity testing. RESULTS: Fifty-six patients were identified; 26 (46%) of the 56 patients experienced partial response, 24 (43%) of 56 experienced stable disease, and 6 (11%) of 56 experienced progression of disease. O-methylguanine DNA methyltransferase status was available for 36 tumors. For tumors with partial response, 10 (67%) of 15 were MGMT deficient, and 5 (33%) of 15 were MGMT intact. For tumors with stable disease, 7 (47%) of 15 were MGMT deficient, and 8 (53%) of 15 were MGMT intact. For tumors with progression of disease, 3 (50%) of 6 were MGMT deficient, and 3 (50%) of 6 were MGMT intact. CONCLUSIONS: We observed response and resistance to alkylating agents in MGMT-deficient and MGMT-intact tumors. O-methylguanine DNA methyltransferase status should not guide alkylating agent therapy in WD panNETs.

Duke Scholars

Published In

Pancreas

DOI

EISSN

1536-4828

Publication Date

July 2017

Volume

46

Issue

6

Start / End Page

758 / 763

Location

United States

Related Subject Headings

  • Young Adult
  • Tumor Suppressor Proteins
  • Treatment Outcome
  • Time Factors
  • Temozolomide
  • Sequence Analysis, DNA
  • Promoter Regions, Genetic
  • Pharmacogenetics
  • Pancreatic Neoplasms
  • Neuroendocrine Tumors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Raj, N., Klimstra, D. S., Horvat, N., Zhang, L., Chou, J. F., Capanu, M., … Reidy-Lagunes, D. (2017). O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas, 46(6), 758–763. https://doi.org/10.1097/MPA.0000000000000842
Raj, Nitya, David S. Klimstra, Natally Horvat, Liying Zhang, Joanne F. Chou, Marinela Capanu, Olca Basturk, Richard Kinh Gian Do, Peter J. Allen, and Diane Reidy-Lagunes. “O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.Pancreas 46, no. 6 (July 2017): 758–63. https://doi.org/10.1097/MPA.0000000000000842.
Raj, Nitya, et al. “O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.Pancreas, vol. 46, no. 6, July 2017, pp. 758–63. Pubmed, doi:10.1097/MPA.0000000000000842.
Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, Basturk O, Do RKG, Allen PJ, Reidy-Lagunes D. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas. 2017 Jul;46(6):758–763.

Published In

Pancreas

DOI

EISSN

1536-4828

Publication Date

July 2017

Volume

46

Issue

6

Start / End Page

758 / 763

Location

United States

Related Subject Headings

  • Young Adult
  • Tumor Suppressor Proteins
  • Treatment Outcome
  • Time Factors
  • Temozolomide
  • Sequence Analysis, DNA
  • Promoter Regions, Genetic
  • Pharmacogenetics
  • Pancreatic Neoplasms
  • Neuroendocrine Tumors